March 20, 2014
WASHINGTON, D.C. — Rx Response, the highly acclaimed initiative of the bio-pharmaceutical supply chain to help ensure the continued flow of medicine to patients in times of emergency, has established a new membership structure that will enable individual companies in the bio-pharmaceutical supply chain to become direct members.
The move opens the door for individual companies to enhance their disaster preparedness and response capabilities by tapping Rx Response’s accurate and timely information, direct support during disasters, government relationships and industry networking. Individual supply chain companies that join Rx Response will also increase the program’s situational awareness by providing a broader source of reports about the impact of a disaster on the supply chain members.
Rx Response provides a platform through which the entire bio-pharmaceutical supply system can easily communicate to coordinate pre-disaster planning and post-disaster response. Rx Response also serves as a single point of contact through which government officials and supply chain members can liaise to share information and address challenges impacting the supply system.
In addition to restructuring its membership, Rx Response also announced today that it has received official approval from the IRS for its application to become a 501(c)(3) non-profit organization. The approval will make it easier for Foundations, non-profit organizations and government agencies to provide grants to Rx Response. The 501(c)(3) designation will not change the operational components of the program and government officials will still be able to participate at no cost.
Since its inception in 2007, Rx Response has earned a reputation as an indispensible homeland security asset, gaining recognition from federal and state officials for its response to numerous disasters. Rx Response’s actions following Hurricane Sandy earned praise from Homeland Security Secretary Janet Napolitano, who thanked Rx Response leaders for the program’s post-Sandy actions.
Initial members of the newly formed Rx Response Board of Directors include Phyllis Arthur, MBA, Senior Director for Vaccines, Immunotherapeutics, and Diagnostics Policy, Biotechnology Industry Organization (BIO); Perry Fri, Executive Vice President of Industry Relations, Membership & Education for the Healthcare Distribution Management Association (HDMA); Kathleen Jaeger, Senior Vice President for Pharmacy Care and Patient Advocacy for the National Association of Chain Drug Stores (NACDS) and President of the NACDS Foundation; Mary Lockyear, Manager of Disaster Health Services for the American Red Cross; Del Persinger, Executive Vice President and CFO of the Pharmaceutical Research and Manufacturers of America (PhRMA); Christine Simmon, Senior Vice President, Policy & Strategic Alliances for the Generic Pharmaceutical Association of America (GPhA); and Erin Mullen, RPh, PhD, CEM, Executive Director of Rx Response.
Rx Response was created in the aftermath of Hurricane Katrina when members of the bio-pharmaceutical supply chain realized that a critical factor in preserving and protecting public health was ensuring continued access to essential medicines. In the years since, Rx Response has evolved into a highly sophisticated information-sharing and problem-solving entity that has become an indispensable homeland security asset.
Rx Response members span the entire private sector bio-pharmaceutical supply system and include manufacturers, distributors, and dispensers (pharmacies & hospitals), as well as disaster relief organizations. Rx Response’s operations are supported by state-of-the art technology, tested plans, and a team of personnel that is ready for response. Rx Response has provided emergency management and public health officials with unprecedented access to the bio-pharmaceutical supply chain, acting as a single point of contact that can share information about the status of the bio-pharmaceutical supply chain or help resolve obstacles to the flow of medicines.
Follow @RxResponse on Twitter for the latest Emergency Preparedness issues and events.
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and more than 200,000 pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.